TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01203072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 5mg tablets oral, once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 15mg tablets, oral once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 30 mg tablets, oral, once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b
Description: DU-176b 60 mg tablets, oral, once daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablets, once daily for 2 weeks
Study: NCT00235872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg eow, sc
Study: NCT01450410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid
Description: Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment will last for 12 weeks.
Study: NCT02972632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablet
Study: NCT02032147

Intervention type: DRUG
Intervention: NGF group
Description: This group will be treated with NGF 18u per day im for 60 days
Study: NCT04738110

Intervention type: OTHER
Intervention: MRI
Description: Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
Study: NCT02477215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine (multiple dose levels)
Description: 70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine (MTD)
Description: 80 mg/m\^2 on days 1 and 2
Study: NCT00960323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
Study: NCT03534089

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant fomula
Description: Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level LF infant formula
Description: Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High level LF infant formula
Description: Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
Study: NCT02785588

Intervention type: DEVICE
Group type: OTHER
Intervention: 3.0 T Neonatal MRI scanner
Description: eligible subjects will undergo neonatal MRI scan procedure
Study: NCT01332422

Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Description: Collection of safety data
Study: NCT01990417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching
Description: Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
Study: NCT00995202

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Monitoring CEA
Description: No specific follow-up of CEA

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Monitoring CEA
Description: No specific follow-up of CEA
Study: NCT02220517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided in-bore prostate biopsy
Description: Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/US fusion-guided prostate biopsy
Description: Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
Study: NCT03791463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolic acid A
Description: Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolic acid A
Description: Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
Study: NCT03075020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon monoxide
Description: carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
Study: NCT04180072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
Study: NCT02652455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
Study: NCT03075020

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AIR
Description: Room air will be administered as placebo
Study: NCT00984724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
Study: NCT02652455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to Remove Tumor for Growth of TIL
Description: All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD137
Description: All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
Study: NCT00984724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
Study: NCT02652455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL Infusion
Description: After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
Study: NCT00984724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Description: Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.
Study: NCT02652455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, in-patient high dose IL-2 treatment.
Study: NCT00739388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
Study: NCT00984724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.
Study: NCT04043663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality glasses
Description: Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
Study: NCT00984724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Letter referring participants to a Quitline providing quit smoking services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 300 pieces of nicotine gum issued at baseline visit.
Study: NCT00995202

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive Monitoring CEA
Description: CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive Monitoring CEA
Description: CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Monitoring Imagery
Description: Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Monitoring Imagery
Description: Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive Monitoring Imagery
Description: Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive Monitoring Imagery
Description: Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
Study: NCT01134458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Intervention
Description: 1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight
Study: NCT04522349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Greifer then Axon-Hook
Description: Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
Study: NCT04043663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard perioperative care without virtual reality program
Description: standard perioperative care without virtual reality program
Study: NCT02705456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing HA
Description: 2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Brushing FL
Description: 2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks).
Study: NCT01678755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 High Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02054000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Intracoronary administering of Tirofiban
Study: NCT04522349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axon-Hook then Greifer
Description: Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
Study: NCT02054000

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracoronary serum physiologic
Study: NCT00022490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
Study: NCT00984724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 300 pieces of nicotine gum issued at baseline visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 300 pieces of nicotine gum issued at baseline visit.
Study: NCT03786887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: dosage of nalbuphine
Study: NCT00237978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalen
Study: NCT03881137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment with management
Description: A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT.
Study: NCT02221258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-RA Inj.
Description: Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
Study: NCT00237978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalen

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VIS and wIRA

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VIS and wIRA
Study: NCT02172807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low
Description: Tiotropium 18 µg inhalation capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high
Description: Tiotropium 36 µg inhalation capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI
Description: Placebo metered dose inhaler (MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI
Description: Placebo metered dose inhaler (MDI)
Study: NCT00526760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT02917369

Intervention type: OTHER
Intervention: Normal lung tissue
Description: The investigators will extract total protein, DNA and RNA from LCLC patients.

Intervention type: OTHER
Intervention: Normal lung tissue
Description: The investigators will extract total protein, DNA and RNA from LCLC patients.

Intervention type: OTHER
Intervention: Normal lung tissue
Description: The investigators will extract total protein, DNA and RNA from LCLC patients.
Study: NCT02172807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhalation capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxitropium
Description: Oxitropium MDI (100 µg/puff)
Study: NCT00473590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m\^2 administered by intravenous bolus injection
Study: NCT03278834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular muscle stimulation machine- Strength Setting
Description: Muscle stimulation to strength skeletal muscle

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular muscle stimulation machine - TENS Setting
Description: Muscle stimulation to mimic the intervention but without the strength gains.
Study: NCT00473590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3 mg/m\^2 administered by intravenous bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT03653988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEC I/II blocks by anesthesiologist - pre-operative
Description: PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
Study: NCT01130662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy using decitabine and midostaurin
Description: Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle.